Objective motor assessment for PD clinical trials
Digital kinematic endpoints for Parkinson's disease from digitized spiral analysis capture bradykinesia, rigidity-related pressure changes, tremor, and coordination from a brief drawing assessment. NeuroQuantix complements the established MDS-UPDRS Part III with continuous, domain-specific motor measurement that adds the precision needed to detect smaller treatment effects in PD clinical trials.
Published effect sizes on digitized spiral analysis enable smaller, faster trials with objective, regulatory-grade endpoints. NeuroQuantix standardizes this evidence into a pre-specified endpoint for your program. Learn more about parkinson's disease from the NINDS/NIH overview.
Limitations of MDS-UPDRS
The Movement Disorder Society Unified Parkinson Disease Rating Scale Part III (MDS-UPDRS) is the current gold standard for parkinson's disease assessment in clinical trials. These are its documented limitations. See the FDA guidance for parkinson's disease for regulatory context.
The PD Motor Assessment Challenge
MDS-UPDRS Part III combines 18 items across diverse motor domains into a single composite score — a structure that has served PD trials well by providing a single comparable global measure with strong regulatory precedent. The opportunity is to pair MDS-UPDRS with continuous, domain-specific kinematic measurement that preserves the signal from each motor domain individually. For gene therapy programs targeting specific PD subtypes (GBA1, LRRK2, SNCA), where every enrollment slot counts, the added precision from digital endpoints can determine whether a powered study is feasible.
Clinical Applications
Published Evidence
Evidence from peer-reviewed publications supporting digital kinematic endpoints for parkinson's disease assessment. View the full evidence base.
CISP Composite Index
The Composite Index of Speed and Pressure combines drawing velocity and pen force into a single metric that captures bradykinesia (the cardinal PD motor sign) with strong discriminative performance.
Zham P, et al. Frontiers in Neurology, 2017Levodopa Responsiveness
Published studies demonstrate that RMSE and smoothness metrics detect levodopa on/off transitions, validating sensitivity to dopaminergic treatment effects.
Galli M, et al. J Applied Biomechanics, 2014
Multi-Domain Capture
A brief drawing assessment captures tremor, bradykinesia, rigidity-related pressure changes, and coordination metrics. Each domain is preserved separately rather than averaged into a composite.
Published literature across multiple research groups
DBS On/Off Discrimination
Published validation demonstrates that RMSE and degree of smoothness metrics discriminate DBS on vs. off states, providing objective confirmation of stimulation efficacy and supporting longitudinal outcome tracking.
Pullman SL, et al. Clinical Neurology & Neurosurgery, 2021Statistical Power Advantage
Higher measurement precision translates directly into smaller enrollment requirements. See the full interactive power curve comparison on the NeuroQuantix platform page.
View Power VisualizationFrequently Asked Questions
What digital biomarkers are used for Parkinson's disease assessment?
NeuroQuantix extracts digital biomarkers for Parkinson's disease from a brief spiral drawing assessment, including the Composite Index of Speed and Pressure (CISP), pen tilt-pressure analysis, motor smoothness (SPARC), and a range of acceleration and jerk metrics. Each metric maps to a specific aspect of PD motor pathophysiology — bradykinesia, rigidity, tremor, and coordination — providing domain-specific signal that complements the global MDS-UPDRS Part III score.
How does NeuroQuantix work alongside MDS-UPDRS in PD clinical trials?
MDS-UPDRS Part III provides decades of regulatory precedent and clinical interpretability for PD motor assessment. NeuroQuantix complements MDS-UPDRS with continuous, high-frequency kinematic measurement that decomposes the global motor picture into bradykinesia-, rigidity-, tremor-, and coordination-specific signals. Many modern PD trial designs use both — MDS-UPDRS as the regulatorily-precedented endpoint and digital kinematic endpoints to improve sensitivity and increase the probability of detecting real treatment effects.
How does NeuroQuantix provide objective Parkinson disease assessment?
NeuroQuantix captures bradykinesia, rigidity-related pressure changes, tremor, and coordination from a brief drawing assessment at 240 samples per second. Each motor domain is preserved separately rather than averaged into a composite score, enabling domain-specific treatment effect detection that complements the global picture provided by clinical rating scales.
What does the published evidence support for PD digital kinematic endpoints?
Published literature on digitized spiral analysis demonstrates strong discriminative performance for PD detection (CISP composite, pen tilt-pressure analysis), sensitivity to levodopa on/off transitions, and discrimination of DBS on vs. off states. The 3D hand dynamics captured via stylus altitude and azimuth represent measurement dimensions that ordinal clinical scales cannot capture.
Explore Further
23 Conditions
Full differential with evidence tiers and gene therapy applications.
NeuroQuantix Platform
Regulatory-grade digital endpoints backed by published effect sizes.
Published Research
Scoping review of 120 studies in Movement Disorders Clinical Practice.
Endpoint Consulting
Strategic endpoint selection for your parkinson's disease program.
Essential Tremor
Digital kinematic endpoints for essential tremor clinical trials.
Dystonia
Digital kinematic endpoints for dystonia clinical trials.
Ready to discuss parkinson's disease endpoints?
Schedule a consultation to explore how precision digital endpoints can strengthen your parkinson's disease clinical program.